INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 41 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $2,749,986,000 | -26.8% | 3,418,000 | -32.1% | 0.00% | -42.9% |
| Q2 2020 | $3,754,617,000 | +57.2% | 5,033,000 | +69.9% | 0.01% | +40.0% |
| Q1 2020 | $2,387,840,000 | +66.8% | 2,962,000 | +108.3% | 0.01% | +66.7% |
| Q4 2019 | $1,431,328,000 | -10.4% | 1,422,000 | -20.6% | 0.00% | 0.0% |
| Q2 2019 | $1,597,783,000 | +31.0% | 1,792,000 | +45.3% | 0.00% | 0.0% |
| Q1 2019 | $1,220,140,000 | – | 1,233,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Silver Point Capital L.P. | 57,420,000 | $44,527,000 | 5.17% |
| Birch Grove Capital LP | 10,003,000 | $7,934,000 | 4.14% |
| PenderFund Capital Management Ltd. | 9,605,000 | $9,491,000 | 2.41% |
| Context Capital Management, LLC | 9,887,000 | $7,671,000 | 1.05% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 57,791,000 | $45,738,000 | 0.90% |
| DeepCurrents Investment Group LLC | 35,892,000 | $27,953,000 | 0.74% |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 22,977,000 | $18,267,000 | 0.70% |
| WHITEBOX ADVISORS LLC | 23,150,000 | $17,847,000 | 0.56% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 27,397,000 | $21,720,000 | 0.46% |
| OAKTREE CAPITAL MANAGEMENT LP | 19,435,000 | $15,079,000 | 0.26% |